High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology-Reference-Cited by-同舟云学术

High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology

Published:2018-05-03 Issue:18 Volume:131 Page:2060-2064
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Scott David W.¹²³,King Rebecca L.⁴³,Staiger Annette M.⁵⁶³,Ben-Neriah Susana¹³,Jiang Aixiang⁷³,Horn Heike⁶³,Mottok Anja¹⁸³,Farinha Pedro¹³,Slack Graham W.¹³,Ennishi Daisuke¹³,Schmitz Norbert⁹³,Pfreundschuh Michael⁹³,Nowakowski Grzegorz S.¹⁰³,Kahl Brad S.¹¹³,Connors Joseph M.¹²³,Gascoyne Randy D.¹³,Ott German⁵³,Macon William R.⁴³,Rosenwald Andreas⁸³

Affiliation:

1. Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, Canada;

2. Department of Medicine, University of British Columbia, Vancouver, Canada;

3. Washington University School of Medicine, St. Louis, MO

4. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN;

5. Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany;

6. Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tuebingen, Tuebingen, Germany;

7. Department of Molecular Biology and Biochemistry, Simon Fraser University, Vancouver, Canada;

8. Institute of Pathology, Würzburg University and Comprehensive Cancer Center Mainfranken, Würzburg, Germany;

9. Department of Medicine, Hematology and Oncology, University Hospital Muenster, Muenster, Germany;

10. Department of Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany;

11. Department of Oncology, Mayo Clinic, Rochester, MN; and

Abstract

Key Points HGBL-DH/TH makes up 8% of de novo DLBCL, with HGBL-DH/TH with BCL2 rearrangement being a GCB phenomenon. Restricting FISH testing to tumors with dual protein expression and GCB subtype results in testing <15% of tumors, but missing ∼35% of HGBL-DH/TH.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/131/18/2060/1405722/blood820605.pdf

Reference21 articles.

1. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues;Swerdlow,2017

2. Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment;Obermann;J Clin Pathol,2009

3. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma;Ye;Oncotarget,2016

4. MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations;Pedersen;Eur J Haematol,2014

5. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study;Copie-Bergman;Blood,2015

Cited by 176 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation;Nature Communications;2024-08-08

2. Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study);Blood;2024-08-01

3. Advances in biology, diagnosis and treatment of DLBCL;Annals of Hematology;2024-07-17

4. Lymphoma Classifications, How to Develop a Future Unified Taxonomy;Journal of Clinical Oncology;2024-07-17

5. Turning the tide in aggressive lymphoma: liquid biopsy for risk-adapted treatment strategies;Trends in Molecular Medicine;2024-07